(Q44467962)

3 December 2017

title

Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. (English)

1 reference

3 December 2017

1 reference

11

Raymond F Schinazi

1 reference

3 December 2017

3

Guoen Shi

1 reference

3 December 2017

author name string

Susan Erickson-Viitanen

1

1 reference

3 December 2017

Jing-Tao Wu

2

1 reference

3 December 2017

Steven Unger

4

1 reference

3 December 2017

Robert W King

5

1 reference

3 December 2017

Barbara Fish

6

1 reference

3 December 2017

Ronald Klabe

7

1 reference

3 December 2017

Romas Geleziunas

8

1 reference

3 December 2017

Karen Gallagher

9

1 reference

3 December 2017

Michael J Otto

10

1 reference

3 December 2017

publication date

1 January 2003

1 reference

Antiviral Chemistry & Chemotherapy

3 December 2017

published in

1 reference

3 December 2017

volume

14

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

39-47

1 reference

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

HIV drug resistance--a chink in the armor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Resistance against reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400104

10.1177/095632020301400104

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference